{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-06-03T05:25:01.949428+00:00","company":{"ticker":"OFIX","cik":884624,"company_name":"Orthofix Medical Inc."},"pagination":{"limit":100,"returned":7,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","facts":[{"fact_type":"earnings_release","fact_key":"a5379e600572296edcaf098ea718d7b8acfa9f29","cik":884624,"ticker":"OFIX","company_name":"Orthofix Medical Inc.","filed_at":"2026-05-05T23:59:59+00:00","payload":{"eps_text":"$(0.52) per share","guidance_signal":"reaffirmed","item_codes_triggered":["2.02"],"net_income_text":"$(20.9) million","period_text":"the first quarter ended March 31, 2026","report_date":"2026-05-05","result_type":"reported_results","revenue_text":"$196.7 million"},"claim":"Orthofix Medical Inc. reported the first quarter ended March 31, 2026 results: revenue $196.7 million, net income $(20.9) million, EPS $(0.52) per share. Guidance reaffirmed.","evidence_excerpt":"measures contained within this release exclude the impact of the Company’s decision to discontinue its M6TM product lines. Highlights • First quarter 2026 reported net sales of $196.7 million, including sales from M6 artificial cervical and lumbar discs. Non-GAAP pro forma net sales of $196.4 million, excluding sales from M6 discs, increased 3% year over year on a","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-26-204999","anchor_url":"https://secwatch.observer/filing/0001193125-26-204999#claim-a5379e600572296edcaf098ea718d7b8acfa9f29","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/884624/000119312526204999/0001193125-26-204999-index.htm"},{"fact_type":"earnings_release","fact_key":"8b9ed3eaa040e0da8d686748ff56020e49a4ce2d","cik":884624,"ticker":"OFIX","company_name":"Orthofix Medical Inc.","filed_at":"2026-04-09T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"reaffirmed","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"full-year 2026","report_date":"2026-04-09","result_type":"guidance_update","revenue_text":"$850 million to $860 million"},"claim":"Orthofix Medical Inc. reported full-year 2026 results: revenue $850 million to $860 million. Guidance reaffirmed.","evidence_excerpt":"The company also reaffirmed its full-year 2026 guidance as follows: • Net sales expected to range between $850 million to $860 million. The Company’s expected net sales represent implied year-over-year pro forma constant currency growth of approximately 5.5% at the midpoint of the range. This guidance range is based on current foreign currency exchange rates and does not take into account any additional potential exchange rate changes that may occur this year. • Non-GAAP adjusted EBITDA expected to be $95 million to $98 million. This represents 70 basis points of non-GAAP adjusted EBITDA margin expansion at the midpoint of the range compared to 2025. • Free cash flow expected to be positive for full-year 2026, excluding the impact of any potential legal settlements.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-26-148853","anchor_url":"https://secwatch.observer/filing/0001193125-26-148853#claim-8b9ed3eaa040e0da8d686748ff56020e49a4ce2d","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/884624/000119312526148853/0001193125-26-148853-index.htm"},{"fact_type":"earnings_release","fact_key":"d1f6ffb7544b5871c9a025c7e3874c7e2edf2618","cik":884624,"ticker":"OFIX","company_name":"Orthofix Medical Inc.","filed_at":"2026-04-09T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"first quarter ended March 31, 2026","report_date":"2026-04-09","result_type":"preliminary_results","revenue_text":"$196.7 million"},"claim":"Orthofix Medical Inc. reported first quarter ended March 31, 2026 results: revenue $196.7 million.","evidence_excerpt":"Orthofix today reported preliminary, unaudited first quarter 2026 net sales of approximately $196.7 million, including sales from M6 artificial cervical and lumbar discs, and non-GAAP pro forma net sales of approximately $196.4 million, excluding sales from M6 discs, representing an increase of 0.4% on a reported basis and 3% on a non-GAAP pro forma constant currency basis compared to Q1 2025.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-26-148853","anchor_url":"https://secwatch.observer/filing/0001193125-26-148853#claim-d1f6ffb7544b5871c9a025c7e3874c7e2edf2618","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/884624/000119312526148853/0001193125-26-148853-index.htm"},{"fact_type":"executive_change","fact_key":"f9e9a4046c","cik":884624,"ticker":"OFIX","company_name":"Orthofix Medical Inc.","filed_at":"2025-03-12T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2025-03-11","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Vickie Capps was appointed as Director at Orthofix Medical Inc..","evidence_excerpt":"appointed Vickie Capps as a director.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0000950170-25-037630","anchor_url":"https://secwatch.observer/filing/0000950170-25-037630#claim-f9e9a4046c","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/884624/000095017025037630/0000950170-25-037630-index.htm"},{"fact_type":"executive_change","fact_key":"0174bbb121","cik":884624,"ticker":"OFIX","company_name":"Orthofix Medical Inc.","filed_at":"2024-06-20T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2024-06-18","interim":false,"role":"Chair of the Board","role_category":"chair","successor_name":null,"successor_named":false},"claim":"Michael M. Finegan was appointed as Chair of the Board at Orthofix Medical Inc..","evidence_excerpt":"At its meeting on June 18, 2024, the Company’s Board of Directors (the “Board”) unanimously appointed (i) Michael M. Finegan as Chair of the Board","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0000950170-24-075288","anchor_url":"https://secwatch.observer/filing/0000950170-24-075288#claim-0174bbb121","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/884624/000095017024075288/0000950170-24-075288-index.htm"},{"fact_type":"executive_change","fact_key":"986e9bde31","cik":884624,"ticker":"OFIX","company_name":"Orthofix Medical Inc.","filed_at":"2024-06-20T23:59:59+00:00","payload":{"action":"departing","action_category":"departure","departure_tone":"routine","effective_date":"2024-07-05","interim":false,"role":"President, Global Orthopedics","role_category":"other_named_officer","successor_name":null,"successor_named":false},"claim":"Kimberley A. Elting departed as President, Global Orthopedics at Orthofix Medical Inc..","evidence_excerpt":"On June 20, 2024, the Company announced that Kimberley A. Elting, the Company’s President, Global Orthopedics, will be departing as an executive and employee on or about July 5, 2024.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0000950170-24-075288","anchor_url":"https://secwatch.observer/filing/0000950170-24-075288#claim-986e9bde31","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/884624/000095017024075288/0000950170-24-075288-index.htm"},{"fact_type":"earnings_release","fact_key":"03ecbc02f5984a634fc907a1b8c6bfd4001828b8","cik":884624,"ticker":"OFIX","company_name":"Orthofix Medical Inc.","filed_at":"2024-05-07T23:59:59+00:00","payload":{"eps_text":"$(0.95)","guidance_signal":"raised","item_codes_triggered":["2.02"],"net_income_text":"$(36.0) million","period_text":"the first quarter ended March 31, 2024","report_date":"2024-05-07","result_type":"reported_results","revenue_text":"$188.6 million"},"claim":"Orthofix Medical Inc. reported the first quarter ended March 31, 2024 results: revenue $188.6 million, net income $(36.0) million, EPS $(0.95). Guidance raised.","evidence_excerpt":"assets, and any impairment of acquired goodwil\n\n--- EX-99.1 (EX-99.1) ---\n\nEX-99.1 Exhibit 99.1 Orthofix Reports First Quarter 2024 Results Recent Highlights • Net sales of $188.6 million, an increase of 7.7% on a reported basis and 7.5% on a constant currency basis over prior year • Bone Growth Therapies net sales growth of 10%, marking five consecutive quarters","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0000950170-24-053961","anchor_url":"https://secwatch.observer/filing/0000950170-24-053961#claim-03ecbc02f5984a634fc907a1b8c6bfd4001828b8","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/884624/000095017024053961/0000950170-24-053961-index.htm"}]}